Frequency of non-JAK2V617F mutations prior to PEG-IFN-α-2a therapy
| Mutated gene . | Overall cohort (n = 71) . | JAK2V617F mutant . | Non-JAK2V617F mutant . | |||||
|---|---|---|---|---|---|---|---|---|
| CMR (n = 10) . | PMR (n = 18) . | mMR (n = 5) . | No molecular response (n = 13) . | CHR (n = 16) . | PHR (n = 5) . | No response (n = 4) . | ||
| TET2 | 16.9% (12/71) | 10% (1/10) | 27.8% (5/18) | 20% (1/5) | 23.1% (3/13) | 1/16 | 0/5 | 1/4 |
| DNMT3A | 12.6% (9/71) | 10% (1/10) | 11.1% (2/18) | 20% (1/5) | 30.8% (4/13) | 1/16 | 0/5 | 0/4 |
| ASXL1 | 4.2% (3/71) | 10% (1/10) | 5.6% (1/18) | 20% (1/5) | 7.7% (1/13) | 0/16 | 0/5 | 0/4 |
| EZH2 | 1.4% (1/71) | 10% (1/10) | 0% (0/18) | 0% (0/5) | 0% (0/13) | 0/16 | 0/5 | 0/4 |
| IDH1/2 | 1.4% (1/71) | 0% (0/10) | 0% (0/18) | 20% (1/5) | 0% (0/13) | 0/16 | 0/5 | 0/4 |
| Overall mutational frequency | 30% | 56% | 12% | |||||
| Mutated gene . | Overall cohort (n = 71) . | JAK2V617F mutant . | Non-JAK2V617F mutant . | |||||
|---|---|---|---|---|---|---|---|---|
| CMR (n = 10) . | PMR (n = 18) . | mMR (n = 5) . | No molecular response (n = 13) . | CHR (n = 16) . | PHR (n = 5) . | No response (n = 4) . | ||
| TET2 | 16.9% (12/71) | 10% (1/10) | 27.8% (5/18) | 20% (1/5) | 23.1% (3/13) | 1/16 | 0/5 | 1/4 |
| DNMT3A | 12.6% (9/71) | 10% (1/10) | 11.1% (2/18) | 20% (1/5) | 30.8% (4/13) | 1/16 | 0/5 | 0/4 |
| ASXL1 | 4.2% (3/71) | 10% (1/10) | 5.6% (1/18) | 20% (1/5) | 7.7% (1/13) | 0/16 | 0/5 | 0/4 |
| EZH2 | 1.4% (1/71) | 10% (1/10) | 0% (0/18) | 0% (0/5) | 0% (0/13) | 0/16 | 0/5 | 0/4 |
| IDH1/2 | 1.4% (1/71) | 0% (0/10) | 0% (0/18) | 20% (1/5) | 0% (0/13) | 0/16 | 0/5 | 0/4 |
| Overall mutational frequency | 30% | 56% | 12% | |||||